{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:18:43Z","timestamp":1792703923832,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.urolonc.2024.01.013","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T08:11:53Z","timestamp":1706170313000},"page":"70.e1-70.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Patient experience and unmet needs in high-risk nonmuscle-invasive bladder cancer: Insights from qualitative interviews and a cross-sectional survey"],"prefix":"10.1016","volume":"42","author":[{"given":"Lewis","family":"Kopenhafer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slaven","family":"Sikirica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth T.","family":"Masters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C.","family":"Cappelleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia Y.","family":"Peck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine C.","family":"Maculaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.urolonc.2024.01.013_bib0001","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","article-title":"The global burden of urinary bladder cancer: an update","volume":"38","author":"Richters","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2024.01.013_bib0002","unstructured":"World Cancer Research Fund. Bladder cancer statistics. Accessed March 17, 2023. https:\/\/www.wcrf.org\/cancer-trends\/bladder-cancer-statistics\/."},{"issue":"1","key":"10.1016\/j.urolonc.2024.01.013_bib0003","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European association of urology guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.01.013_bib0004","first-page":"e126","article-title":"Non muscle invasive bladder cancer treatment","volume":"1","author":"Cavaliere","year":"2014","journal-title":"World Cancer Res J"},{"issue":"3","key":"10.1016\/j.urolonc.2024.01.013_bib0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.3800","article-title":"Estimated costs and long-term outcomes of patients with high-risk nonmuscle-invasive bladder cancer treated with Bacillus Calmette-Gu\u00e9rin in the Veterans Affairs health system","volume":"4","author":"Williams","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.urolonc.2024.01.013_bib0006","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2024.01.013_bib0007","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/CEOR.S274951","article-title":"Humanistic and economic burden of nonmuscle invasive bladder cancer: results of two systematic literature reviews","volume":"12","author":"Lee","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"issue":"10","key":"10.1016\/j.urolonc.2024.01.013_bib0008","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.urolonc.2021.05.015","article-title":"Nonmuscle-invasive bladder cancer: an overview of potential new treatment options","volume":"39","author":"Shore","year":"2021","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.01.013_bib0009","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.juro.2013.08.022","article-title":"The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical Bacillus Calmette-Gu\u00e9rin","volume":"191","author":"Sfakianos","year":"2014","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.01.013_bib0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.urolonc.2024.01.013_bib0011","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/jjco\/hyt086","article-title":"Adverse reactions related to treatment compliance during BCG maintenance therapy for nonmuscle-invasive bladder cancer","volume":"43","author":"Miyazaki","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.01.013_bib0012","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.urology.2018.04.039","article-title":"Patient compliance with maintenance intravesical therapy for nonmuscle invasive bladder cancer","volume":"118","author":"Tapiero","year":"2018","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.urolonc.2024.01.013_bib0013","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000430501","article-title":"Does the compliance to intravesical BCG differ between common clinical practice and international multicentric trials?","volume":"96","author":"Serretta","year":"2016","journal-title":"Urol Int"},{"issue":"11","key":"10.1016\/j.urolonc.2024.01.013_bib0014","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1080\/17512433.2021.1950531","article-title":"Immunotherapy of high risk non-muscle invasive bladder cancer","volume":"14","author":"Ahdoot","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.01.013_bib0015","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2217\/fon-2021-0781","article-title":"Immunotherapy for non-muscle-invasive bladder cancer: from the origins of BCG to novel therapies","volume":"18","author":"Unsworth-White","year":"2022","journal-title":"Futur Oncol"},{"key":"10.1016\/j.urolonc.2024.01.013_bib0016","unstructured":"Atezolizumab plus one-year BCG bladder instillation in BCG-naive high-risk non-muscle invasive bladder cancer patients (ALBAN). ClinicalTrials.gov identifier: NCT03799835. Updated May 31, 2022. Accessed March 17, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03799835."},{"key":"10.1016\/j.urolonc.2024.01.013_bib0017","unstructured":"Assessment of efficacy and safety of durvalumab plus BCG compared to the standard therapy with BCG in non-muscle invasive bladder cancer (POTOMAC). ClinicalTrials.gov identifier: NCT03528694. Updated February 15, 2023. Accessed March 17, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03528694."},{"key":"10.1016\/j.urolonc.2024.01.013_bib0018","unstructured":"Efficacy and safety of pembrolizumab (MK-3475) in combination with Bacillus Calmette-Guerin (BCG) in high-risk non-muscle invasive bladder cancer (HR NMIBC) (MK-3475-676\/KEYNOTE-676). ClinicalTrials.gov identifier: NCT03711032. Updated March 17, 2023. Accessed March 17, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03711032."},{"key":"10.1016\/j.urolonc.2024.01.013_bib0019","unstructured":"A study of sasanlimab in people with non-muscle invasive bladder cancer (CREST). ClinicalTrial.gov identifier: NCT04165317. Updated February 21, 2023. Accessed March 17, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04165317."},{"issue":"1","key":"10.1016\/j.urolonc.2024.01.013_bib0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13104-019-4067-9","article-title":"Comparing the EQ-5D-5L utility index based on value sets of different countries: impact on the interpretation of clinical study results","volume":"12","author":"Gerlinger","year":"2019","journal-title":"BMC Res Notes"},{"issue":"10","key":"10.1016\/j.urolonc.2024.01.013_bib0021","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"5","key":"10.1016\/j.urolonc.2024.01.013_bib0022","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The european organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.urolonc.2024.01.013_bib0023","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.eururo.2014.02.034","article-title":"Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer","volume":"66","author":"Blazeby","year":"2014","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.01.013_bib0024","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.urolonc.2024.01.013_bib0025","series-title":"The SAGE handbook of qualitative research in psychology","article-title":"Thematic analysis","author":"Terry","year":"2017"},{"issue":"1-2","key":"10.1016\/j.urolonc.2024.01.013_bib0026","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/biomet\/38.1-2.141","article-title":"Note on an exact treatment of contingency, goodness of fit and other problems of significance","volume":"38","author":"Freeman","year":"1951","journal-title":"Biometrika"},{"issue":"7","key":"10.1016\/j.urolonc.2024.01.013_bib0027","doi-asserted-by":"crossref","first-page":"A471","DOI":"10.1016\/j.jval.2015.09.1248","article-title":"The impact of nonmuscle invasive bladder cancer: qualitative research with patients","volume":"18","author":"Clark","year":"2015","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.urolonc.2024.01.013_bib0028","first-page":"3877","article-title":"Assessment of quality of life, information, and supportive care needs in patients with muscle and nonmuscle invasive bladder cancer across the illness trajectory","volume":"27","author":"Chung","year":"2019","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2024.01.013_bib0029","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1148\/rg.2019180014","article-title":"Complications of intravesical BCG immunotherapy for bladder cancer","volume":"39","author":"Green","year":"2019","journal-title":"Radiographics"},{"issue":"3","key":"10.1016\/j.urolonc.2024.01.013_bib0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.3816","article-title":"Quantifying the costs of care among patients with high-risk nonmuscle-invasive bladder cancer treated in the Veterans Health Administration","volume":"4","author":"Sanchez","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"Suppl_3","key":"10.1016\/j.urolonc.2024.01.013_bib0031","first-page":"e432","article-title":"The incidence and predictors of financial toxicity in a prospective cohort of patients with nonmuscle invasive bladder cancer","volume":"206","author":"Sharma","year":"2021","journal-title":"J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924000152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924000152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:28:01Z","timestamp":1761042481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924000152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1078143924000152"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.01.013","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient experience and unmet needs in high-risk nonmuscle-invasive bladder cancer: Insights from qualitative interviews and a cross-sectional survey","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}